Following through with a promise delivered on StockTwits last week, “The Vega Group” has published a negative report on GW Pharma (NASDAQ: GWPH) (LON: GWP). The stock had reacted negatively on Thursday when “SyntecVentures” tweeted out its pending release. 
The Vega Group is a “subsidiary of Syntec Ventures”, but there is little information available publicly about either entity, and the report itself was posted to a Google drive. The report, which mistakenly references “GPW” several times, suggests that the fair valuation would be, at best, $52.93 and possibly just $36.28. GWPH stock closed Thursday at $81.63 and is currently near $78, with a low of $77 so far.
Download: GW Pharmaceuticals Research Report Vega Group
Based in Houston, Alan leverages his experience as founder of online community 420 Investor, the first and still largest due diligence platform focused on the publicly-traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. At New Cannabis Ventures, he is responsible for content development and strategic alliances. Before shifting his focus to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst following over two decades in research and portfolio management. A prolific writer, with over 650 articles published since 2007 at Seeking Alpha, where he has 70,000 followers, Alan is a frequent speaker at industry conferences and a frequent source to the media, including the NY Times, the Wall Street Journal, Fox Business, and Bloomberg TV. Contact Alan: Twitter | Facebook | LinkedIn | Email